ClinicalTrials.gg
Active, not recruitingNCT07840066Updated Sep 24, 2026

Probiotics in Wellbeing

An interventional study of Probiotic Supplementation (Lactobacillus plantarum) and Daily oral administration of one matched placebo capsule for 12 weeks. The placebo contains potato starch in place of the probiotic bacterial mass and is matched to the active intervention. in Healthy Participants, sponsored by University of Reading. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by University of Reading · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study will investigate whether taking a probiotic supplement every day for 12 weeks can reduce low-level inflammation and improve wellbeing in generally healthy adults.

Forty adults will be randomly assigned to receive either a probiotic capsule or a placebo capsule that looks the same but does not contain probiotic bacteria. Neither the participants nor the researchers involved in the study will know which treatment each participant receives until the study is completed.

Participants will attend a study visit before starting the supplement and another visit after 12 weeks, with a remote check midway through the study. Blood samples will be collected to measure markers of inflammation and stress. Stool samples will be collected to assess the gut microbiota and substances produced by gut bacteria. Urine samples will also be collected to measure metabolites, which are small molecules produced by normal processes in the body and by interactions between the body, diet and gut microbiota. Participants will also complete questionnaires about wellbeing, mood, anxiety, quality of life and memory.

The main aim of the study is to determine whether the probiotic reduces a combined measure of several markers of inflammation compared with placebo. The study will also explore whether changes in inflammation are associated with changes in wellbeing and memory, and whether these effects are accompanied by changes in the gut microbiota or in metabolic profiles measured in stool and urine.

The results will help researchers understand how probiotics may influence communication between the gut, immune system and brain, and will provide information to help design a larger clinical trial.

Read the detailed description

The gut microbiota can influence host immune function through interactions with the intestinal barrier, microbial metabolites and systemic immune signalling. In turn, systemic inflammatory mediators have been associated with mood, wellbeing and cognitive function. This study will investigate a proposed gut-immune-brain pathway in which modulation of the gut environment by a probiotic intervention may alter systemic inflammatory signalling and thereby influence psychological wellbeing and cognitive function.

This is a 12-week, randomised, double-blind, placebo-controlled, parallel-arm pilot study in 40 generally healthy adults. Following baseline assessments, participants will be randomly allocated to receive either a daily multi-strain probiotic supplement or a matched placebo for 12 weeks. Assessments will take place at baseline and at the end of the 12-week intervention, with a remote adherence and tolerability check approximately halfway through the intervention.

The primary objective is to determine whether probiotic supplementation reduces systemic pro-inflammatory activity compared with placebo. The primary endpoint is the change from baseline to week 12 in a pre-specified pro-inflammatory composite comprising IL-6, TNF-α, IL-1β, IL-8, IFN-γ and high-sensitivity C-reactive protein (hsCRP). Each marker will be standardised relative to its baseline variability and combined into a direction-consistent composite in which higher values indicate greater inflammatory activity.

Secondary assessments will include the anti-inflammatory cytokine IL-10, serum cortisol and validated questionnaires assessing quality of life, depressive symptoms, anxiety, wellbeing and prospective and retrospective memory.

Exploratory mechanistic outcomes will include faecal short-chain fatty acids and related organic acids measured by gas chromatography-mass spectrometry, quantification of selected major bacterial groups using fluorescence in situ hybridisation coupled with flow cytometry, and descriptive 16S rRNA gene sequencing to characterise gut microbial community features. Urine samples collected at baseline and week 12 will undergo nuclear magnetic resonance (NMR) spectroscopy-based metabolomic profiling to assess changes in urinary metabolites associated with the intervention. These analyses will provide an additional measure of host-microbial metabolic activity and will be explored in relation to changes in the gut microbiota, inflammatory markers and wellbeing outcomes.

The study will additionally examine whether within-person reductions in the pro-inflammatory composite are associated with improvements in wellbeing and cognitive measures, whether this relationship differs between the probiotic and placebo groups, and whether baseline inflammatory status modifies the response to the intervention. Exploratory mediation analyses will investigate whether changes in inflammatory activity may partly account for any observed effect of the intervention on wellbeing.

By integrating measures of gut microbial composition and activity, faecal and urinary metabolite profiles, systemic immune signalling and psychological outcomes within a controlled intervention study, the trial aims to improve mechanistic understanding of communication along the gut-immune-brain axis and to provide effect-size and feasibility data for a future larger randomised controlled trial.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

University of Reading is the lead sponsor of 151 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Generally healthy adults
  • Aged 18 to 60 years
  • (BMI) 18.5 to 30 kg/m²

Exclusion criteria

Exclusion Criteria:

  • Antibiotic use within the previous 3 months
  • Chronic gastrointestinal disorders
  • Chronic immune disorders
  • Current probiotic or prebiotic use
  • Current use of immunomodulatory medication
  • Pregnancy or lactation
  • Relevant allergies
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Placebo comparator
    Vegan capsules filled with potato starch only.

    Daily oral administration of one matched placebo capsule for 12 weeks. The placebo contains potato starch in place of the probiotic bacterial mass and is matched to the active intervention in capsule shell, appearance and fill weight. Participants will take one capsule daily with water for 12 weeks, beginning the day after baseline sampling.

    Dietary Supplement: Daily oral administration of one matched placebo capsule for 12 weeks. The placebo contains potato starch in place of the probiotic bacterial mass and is matched to the active intervention.

  • Experimental
    Probiotic supplement

    Daily oral administration of one capsule of a multi-strain probiotic supplement (Optibac "Every Day") for 12 weeks. Each daily dose provides 5 × 10⁹ CFU and contains Lactobacillus rhamnosus Rosell-11 (R0011), Lactobacillus acidophilus/helveticus Rosell-52 (R0052), Bifidobacterium longum Rosell-175 (R0175), Bifidobacterium breve Rosell-70 (R0070), Bifidobacterium bifidum Rosell-71 (R0071), and Lactococcus lactis Rosell-1058 (R1058), together with fructooligosaccharides (FOS). Participants will take one capsule daily with water for 12 weeks, beginning the day after baseline sampling.

    Dietary Supplement: Probiotic Supplementation (Lactobacillus plantarum)

Interventions

  • Dietary supplementLactobacillus plantarumStudies of Lactobacillus plantarumLactobacillus plantarum pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Daily oral administration of one capsule of a multi-strain probiotic supplement (Optibac "Every Day") for 12 weeks. Each daily dose provides 5 × 10⁹ CFU and contains Lactobacillus rhamnosus Rosell-11 (R0011), Lactobacillus acidophilus/helveticus Rosell-52 (R0052), Bifidobacterium longum Rosell-175 (R0175), Bifidobacterium breve Rosell-70 (R0070), Bifidobacterium bifidum Rosell-71 (R0071), and Lactococcus lactis Rosell-1058 (R1058), together with fructooligosaccharides (FOS). Participants will take one capsule daily with water for 12 weeks, beginning the day after baseline sampling.

    Also known as: Optibac Every Day Probiotic

  • Dietary supplementDaily oral administration of one matched placebo capsule for 12 weeks. The placebo contains potato starch in place of the probiotic bacterial mass and is matched to the active intervention.

    Daily oral administration of one matched placebo capsule for 12 weeks. The placebo contains potato starch in place of the probiotic bacterial mass and is matched to the active intervention in capsule shell, appearance and fill weight. Participants will take one capsule daily with water for 12 weeks, beginning the day after baseline sampling.

06

What researchers measure

Primary outcomes

  1. Change in standardised pro-inflammatory biomarker composite

    Change from baseline to Week 12 in a pre-specified pro-inflammatory composite comprising IL-6, TNF-α, IL-1β, IL-8, IFN-γ and high-sensitivity C-reactive protein (hsCRP). Each biomarker will be standardised relative to its baseline distribution and the composite calculated as the mean of direction-consistent z-scores. This is a study-defined continuous composite rather than a bounded clinical scale; therefore, it has no fixed theoretical minimum or maximum. Higher composite values indicate greater systemic inflammatory activity, and a negative change from baseline indicates a reduction in inflammatory activity. The between-group change will be compared between the probiotic and placebo groups.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change in plasma IL-10 concentration

    Change from baseline to Week 12 in plasma interleukin-10 (IL-10), an anti-inflammatory cytokine. IL-10 will be assessed as a secondary marker of anti-inflammatory immune activity.

    Time frame: Baseline and Week 12

  2. Change in serum cortisol concentration

    Change from baseline to Week 12 in serum cortisol concentration as a secondary measure related to physiological stress responses.

    Time frame: Baseline and Week 12

  3. Change in 12-Item Short Form Health Survey Mental Component Summary score

    Change from baseline to Week 12 in mental health-related quality of life assessed using the 12-Item Short Form Health Survey, Version 1 (SF-12v1) Mental Component Summary (MCS). MCS scores range from 0 to 100, with higher scores indicating better mental health-related quality of life. Change will be calculated as Week 12 minus baseline; a positive change indicates improvement.

    Time frame: Baseline and Week 12

  4. Change in 12-Item Short Form Health Survey Physical Component Summary score

    Change from baseline to Week 12 in physical health-related quality of life assessed using the 12-Item Short Form Health Survey, Version 1 (SF-12v1) Physical Component Summary (PCS). PCS scores range from 0 to 100, with higher scores indicating better physical health-related quality of life. Change will be calculated as Week 12 minus baseline; a positive change indicates improvement.

    Time frame: Baseline and Week 12

  5. Change in Patient Health Questionnaire-9 total score

    Change from baseline to Week 12 in depressive symptom severity assessed using the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 total score ranges from 0 to 27, with higher scores indicating greater depressive symptom severity. Change is calculated as Week 12 minus baseline; a negative change indicates improvement.

    Time frame: Baseline and Week 12

  6. Change in Generalized Anxiety Disorder-7 total score

    Change from baseline to Week 12 in anxiety symptom severity assessed using the Generalized Anxiety Disorder-7 (GAD-7). The GAD-7 total score ranges from 0 to 21, with higher scores indicating greater anxiety symptom severity. Change is calculated as Week 12 minus baseline; a negative change indicates improvement.

    Time frame: Baseline and Week 12

  7. Change in World Health Organization-Five Well-Being Index score

    Change from baseline to Week 12 in psychological wellbeing assessed using the World Health Organization-Five Well-Being Index (WHO-5). The raw WHO-5 score ranges from 0 to 25, with higher scores indicating better mental wellbeing. Change is calculated as Week 12 minus baseline; a positive change indicates improvement.

    Time frame: Baseline and Week 12

  8. Change in Prospective and Retrospective Memory Questionnaire total score

    Change from baseline to Week 12 in self-reported everyday memory failures assessed using the 16-item Prospective and Retrospective Memory Questionnaire (PRMQ). The total PRMQ score ranges from 16 to 80, with higher scores indicating more frequent self-reported memory failures and therefore a worse outcome. Change is calculated as Week 12 minus baseline; a negative change indicates improvement.

    Time frame: Baseline and Week 12

Other outcomes

  1. Exploratory differential abundance of faecal bacterial ASVs

    Exploratory assessment of changes from baseline to Week 12 in the abundance of individual amplicon sequence variants identified by 16S rRNA gene sequencing, including comparison of temporal changes between the probiotic and placebo groups.

    Time frame: Baseline and week 12

  2. Faecal bacterial beta diversity assessed by Bray-Curtis dissimilarity

    Differences in overall bacterial community composition according to treatment group and time point will be assessed using Bray-Curtis dissimilarity matrices derived from 16S rRNA gene sequencing, with statistical comparison using permutational multivariate analysis of variance (PERMANOVA). Bray-Curtis dissimilarity ranges from 0 to 1, where 0 indicates identical composition and 1 indicates complete dissimilarity.

    Time frame: Baseline and Week 12

  3. Change in faecal bacterial alpha diversity assessed by Shannon diversity index

    Change from baseline to Week 12 in within-sample bacterial diversity measured using the Shannon diversity index derived from 16S rRNA gene sequencing of stool samples. The Shannon index has a minimum value of 0 and no fixed theoretical maximum; higher values indicate greater bacterial diversity.

    Time frame: Baseline and Week 12

  4. Change in faecal bacterial richness assessed by Chao1 index

    Change from baseline to Week 12 in estimated bacterial richness measured using the Chao1 richness estimator derived from 16S rRNA gene sequencing of stool samples. Chao1 values are non-negative and have no fixed theoretical maximum; higher values indicate greater estimated bacterial richness.

    Time frame: Baseline and Week 12

  5. Change in faecal total bacterial count measured by FISH-FC

    Fluorescent in situ hybridisation coupled with flow cytometry (FISH-FC) will be used to quantify the total number of bacteria in stool samples. This result will complement the 16S rRNA sequencing. Results will be expressed as log10 cells/mL.

    Time frame: Baseline and Week 12

  6. Change in global blood metabolic profile assessed by proton nuclear magnetic resonance spectroscopy

    Change from baseline to Week 12 in the global blood metabolic profile assessed using untargeted proton nuclear magnetic resonance (¹H NMR) spectroscopy. NMR spectral features will be processed and analysed using multivariate metabolomics methods to assess overall differences in metabolic profiles between time points and treatment groups. This is an exploratory, untargeted analysis of the overall metabolic profile rather than separate pre-specified concentrations of individual metabolites; therefore, no fixed minimum or maximum value applies.

    Time frame: Baseline and week 12

  7. Change in global urinary metabolic profile assessed by proton nuclear magnetic resonance spectroscopy

    Change from baseline to Week 12 in the global urinary metabolic profile assessed using untargeted proton nuclear magnetic resonance (¹H NMR) spectroscopy. NMR spectral features will be processed and analysed using multivariate metabolomics methods to assess overall differences in metabolic profiles between time points and treatment groups. This is an exploratory, untargeted analysis of the overall metabolic profile rather than separate pre-specified concentrations of individual metabolites; therefore, no fixed minimum or maximum value applies.

    Time frame: Baseline and Week 12

  8. Change in global faecal metabolic profile assessed by proton nuclear magnetic resonance spectroscopy

    Change from baseline to Week 12 in the global faecal metabolic profile assessed using untargeted proton nuclear magnetic resonance (¹H NMR) spectroscopy. NMR spectral features will be processed and analysed using multivariate metabolomics methods to assess overall differences in metabolic profiles between time points and treatment groups. This is an exploratory, untargeted analysis of the overall metabolic profile rather than separate pre-specified concentrations of individual metabolites; therefore, no fixed minimum or maximum value applies.

    Time frame: Baseline and Week 12

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 24, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Sep 2027
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07840066
Collaborators
Biotechnology and Biological Sciences Research Council, Wren Laboratories LLC
Responsible party
Patricia Sanz Morales (Postdoctoral Researcher, University of Reading) — Principal investigator
First posted
Sep 24, 2026
Start date
Sep 1, 2026
Primary completion
Aug 1, 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lactobacillus plantarum

Start the discussion